The purpose of the Organic Synthesis Core Facility (OSCF) is to provide MSKCC investigators with a fully equipped facility complete with chemistry instrumentation, GMP infrastructure, and staff with the ability to interact with non-chemists as well as chemists, in order to carry out the requested chemical synthesis and consultation. OSCF also assists investigators with pre-clinical and clinical projects. Services are focused on the following: The chemical synthesis of compounds which are not readily available. This is accomplished using established synthetic protocols or by developing new synthetic methodologies. The synthesis of assay development tools and reagents: a) fluorescently labeled compounds, b) affinity labeled compounds, and c) cross linker-tethered molecules. Cold-labeled (13C, 2H, 15N) and radio-labeled (3H, 14C, 1251, 32P, ...etc.) compounds and precursors for preclinical and clinical pharmacological studies which cannot be addressed by the shared Cyclotron- Radiochemistry Core facility. To perform large-scale -cGMP or non-cGMP- chemical syntheses of compounds with demonstrated activity in primary bioassays for preclinical, phase I and II clinical studies (i.e. Le y, Globo H, which are penta- and hexa-carbohydrate antigen vaccine constructs, Cur-61414, peptidyl-Luciferin enzyme activity beacons, and Marimastat) in order to provide sufficient quantities for continued testing. The synthesis of modified and unmodified compounds in amounts that permit their availability for in vitro and in vivo assays and for secondary assays. For example, modifications are introduced to improve solubility, affinity, and specificity. Design, synthesis, and generation of libraries of structurally related compounds based on confirmed hits; library optimization through structure-activity relationships (SAR) identified in a pharmacophore using directed library synthesis and structure-guided design in order to enhance targeting, specificity, and bioavailability while minimizing toxicity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-47S4
Application #
8602877
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-01-20
Project End
2014-12-31
Budget Start
2012-01-09
Budget End
2012-12-31
Support Year
47
Fiscal Year
2013
Total Cost
$315,493
Indirect Cost
$149,094
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Ghasemiesfe, Mehrnaz; Ravi, Divya; Vali, Marzieh et al. (2018) Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis. Ann Intern Med 169:106-115
Benedict, Catherine; DuHamel, Katherine; Nelson, Christian J (2018) Reduction in social activities mediates the relationship between diarrhea and distress in rectal/anal cancer survivors. Psychooncology 27:691-694
Gao, Song; Stein, Seth; Petre, Elena N et al. (2018) Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma. Cardiovasc Intervent Radiol 41:253-259
Perrier, Nancy D; Brierley, James D; Tuttle, R Michael (2018) Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 68:55-63
Jee, David; Yang, Jr-Shiuan; Park, Sun-Mi et al. (2018) Dual Strategies for Argonaute2-Mediated Biogenesis of Erythroid miRNAs Underlie Conserved Requirements for Slicing in Mammals. Mol Cell 69:265-278.e6
Mirpuri, Sheena; Gill, Pavan; Ocampo, Alex et al. (2018) Discrimination and Health Among Taxi Drivers in New York and Toronto. J Community Health 43:667-672
Jones, Christopher W; Misemer, Benjamin S; Platts-Mills, Timothy F et al. (2018) Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study. BMJ Open 8:e019831
Horvat, Natally; Ragucci, Monica; Mannelli, Lorenzo (2018) Hepatic Mass in a Patient With Bladder Cancer History. Gastroenterology 154:493-494
Raghunathan, Nirupa Jaya; Benedict, Catherine; Thom, Bridgette et al. (2018) Young Adult Female Cancer Survivors' Concerns About Future Children's Health and Genetic Risk. J Adolesc Young Adult Oncol 7:125-129
Arvold, Nils D; Armstrong, Terri S; Warren, Katherine E et al. (2018) Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro Oncol 20:897-906

Showing the most recent 10 out of 8799 publications